company background image

Duopharma Biotech Berhad KLSE:DPHARMA Stock Report

Last Price


Market Cap







27 Jun, 2022


Company Financials +
DPHARMA fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance2/6
Financial Health3/6

DPHARMA Stock Overview

Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally.

Duopharma Biotech Berhad Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Duopharma Biotech Berhad
Historical stock prices
Current Share PriceRM1.13
52 Week HighRM2.34
52 Week LowRM1.06
1 Month Change-23.65%
3 Month Change-25.17%
1 Year Change-50.76%
3 Year Change9.98%
5 Year Change60.53%
Change since IPO180.23%

Recent News & Updates

Shareholder Returns

DPHARMAMY PharmaceuticalsMY Market

Return vs Industry: DPHARMA underperformed the MY Pharmaceuticals industry which returned -25.5% over the past year.

Return vs Market: DPHARMA underperformed the MY Market which returned -8.7% over the past year.

Price Volatility

Is DPHARMA's price volatile compared to industry and market?
DPHARMA volatility
DPHARMA Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement3.6%
Market Average Movement5.5%
10% most volatile stocks in MY Market11.5%
10% least volatile stocks in MY Market2.9%

Stable Share Price: DPHARMA is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: DPHARMA's weekly volatility (5%) has been stable over the past year.

About the Company

19781,594Leonard bin Abdul Shatar

Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers antacid, antiflatulant, antiulcerant, antidiarrhoeals, oral electrolyte replacers and anti-inflammatories, antiemietic and antinauseants, systematic antibacterials, antimycobacterials, anti-thrombotic, antihypertensives, antifungals, dermatological, emollients, lipid regulator/anti- antheroma, anaesthetics, psycholeptics, anti-epileptics, systematic antihistamines, opthalmologicals, otological, systemic corticosteroids drugs, and other therapeutic areas. It also provides mineral supplements, functional gastro-intestinal disorder drugs, vitamins, drugs used in diabetes, blood coagulation system, anti-thrombotic agent, renin-angiotensin system agent, lipid-antiotensin system agent, calcium antagonists, beta-blocking agent, cardiac therapy, diuretic, cerebral and peripheral vasotherapeutics, anti-rheumatic products, muscle relaxants, and anti-asthma and COPD products, as well as cough, cold, throat, and nasal preparations.

Duopharma Biotech Berhad Fundamentals Summary

How do Duopharma Biotech Berhad's earnings and revenue compare to its market cap?
DPHARMA fundamental statistics
Market CapRM1.07b
Earnings (TTM)RM68.36m
Revenue (TTM)RM658.66m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DPHARMA income statement (TTM)
Cost of RevenueRM396.58m
Gross ProfitRM262.08m
Other ExpensesRM193.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)0.072
Gross Margin39.79%
Net Profit Margin10.38%
Debt/Equity Ratio65.9%

How did DPHARMA perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is DPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DPHARMA?

Other financial metrics that can be useful for relative valuation.

DPHARMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA11.2x
PEG Ratio2x

Price to Earnings Ratio vs Peers

How does DPHARMA's PE Ratio compare to its peers?

DPHARMA PE Ratio vs Peers
The above table shows the PE ratio for DPHARMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average14.7x
AHEALTH Apex Healthcare Berhad
KOTRA Kotra Industries Berhad
YSPSAH Y.S.P. Southeast Asia Holding Berhad
RHONEMA Rhone Ma Holdings Berhad
DPHARMA Duopharma Biotech Berhad

Price-To-Earnings vs Peers: DPHARMA is expensive based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (14.7x).

Price to Earnings Ratio vs Industry

How does DPHARMA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: DPHARMA is expensive based on its Price-To-Earnings Ratio (15.7x) compared to the MY Pharmaceuticals industry average (13.9x)

Price to Earnings Ratio vs Fair Ratio

What is DPHARMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DPHARMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.7x
Fair PE Ratio22.4x

Price-To-Earnings vs Fair Ratio: DPHARMA is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (22.4x).

Share Price vs Fair Value

What is the Fair Price of DPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DPHARMA (MYR1.13) is trading below our estimate of fair value (MYR1.46)

Significantly Below Fair Value: DPHARMA is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: DPHARMA is poor value based on its PEG Ratio (2x)

Discover undervalued companies

Future Growth

How is Duopharma Biotech Berhad forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DPHARMA's forecast earnings growth (7.8% per year) is above the savings rate (3.6%).

Earnings vs Market: DPHARMA's earnings (7.8% per year) are forecast to grow slower than the MY market (9.9% per year).

High Growth Earnings: DPHARMA's earnings are forecast to grow, but not significantly.

Revenue vs Market: DPHARMA's revenue (7.1% per year) is forecast to grow faster than the MY market (5.2% per year).

High Growth Revenue: DPHARMA's revenue (7.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DPHARMA's Return on Equity is forecast to be low in 3 years time (12.2%).

Discover growth companies

Past Performance

How has Duopharma Biotech Berhad performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DPHARMA has high quality earnings.

Growing Profit Margin: DPHARMA's current net profit margins (10.4%) are lower than last year (10.8%).

Past Earnings Growth Analysis

Earnings Trend: DPHARMA's earnings have grown by 12.9% per year over the past 5 years.

Accelerating Growth: DPHARMA's earnings growth over the past year (9.1%) is below its 5-year average (12.9% per year).

Earnings vs Industry: DPHARMA earnings growth over the past year (9.1%) underperformed the Pharmaceuticals industry 21.4%.

Return on Equity

High ROE: DPHARMA's Return on Equity (10.8%) is considered low.

Discover strong past performing companies

Financial Health

How is Duopharma Biotech Berhad's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: DPHARMA's short term assets (MYR526.3M) exceed its short term liabilities (MYR240.7M).

Long Term Liabilities: DPHARMA's short term assets (MYR526.3M) exceed its long term liabilities (MYR327.8M).

Debt to Equity History and Analysis

Debt Level: DPHARMA's net debt to equity ratio (41.9%) is considered high.

Reducing Debt: DPHARMA's debt to equity ratio has increased from 27.3% to 65.9% over the past 5 years.

Debt Coverage: DPHARMA's debt is not well covered by operating cash flow (15.4%).

Interest Coverage: DPHARMA's interest payments on its debt are well covered by EBIT (17.9x coverage).

Balance Sheet

Discover healthy companies


What is Duopharma Biotech Berhad current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: DPHARMA's dividend (1.92%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (2.15%).

High Dividend: DPHARMA's dividend (1.92%) is low compared to the top 25% of dividend payers in the MY market (4.94%).

Stability and Growth of Payments

Stable Dividend: DPHARMA's dividend payments have been volatile in the past 10 years.

Growing Dividend: DPHARMA's dividend payments have fallen over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (29.5%), DPHARMA's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: DPHARMA is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Leonard bin Abdul Shatar (56 yo)





Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...

CEO Compensation Analysis

Compensation vs Market: Leonard's total compensation ($USD517.62K) is above average for companies of similar size in the MY market ($USD169.79K).

Compensation vs Earnings: Leonard's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: DPHARMA's management team is considered experienced (4.5 years average tenure).

Board Members

Experienced Board: DPHARMA's board of directors are considered experienced (5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Duopharma Biotech Berhad's employee growth, exchange listings and data sources

Key Information

  • Name: Duopharma Biotech Berhad
  • Ticker: DPHARMA
  • Exchange: KLSE
  • Founded: 1978
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: RM1.067b
  • Shares outstanding: 952.24m
  • Website:

Number of Employees


  • Duopharma Biotech Berhad
  • Kenanga International
  • Suite 18.06, Level 18
  • Kuala Lumpur
  • Wilayah Persekutuan
  • 50250
  • Malaysia


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.